Activated neutrophils, recruited to the airway of diseased lung, release human neutrophil peptides (HNP1–4) that are cytotoxic to airway cells as well as microbes. Airway epithelial cells express arginine-specific ADP-ribosyltransferase (ART)-1, a glycophosphatidylinositol-anchored ART that transfers ADP-ribose from NAD to arginines 14 and 24 of HNP-1.We previously reported that ADP-ribosyl-arginine is converted non-enzymatically to ornithine and that ADP-ribosylated HNP-1 and ADP-ribosyl-HNP-(ornithine) were isolated from bronchoalveolar lavage fluid of a patient with idiopathic pulmonary fibrosis, indicating that these reactions occur in vivo. To determine effects of HNP-ornithine on the airway, three analogs of HNP-1, HNP-(R14orn), HNP-(R24orn) and HNP-(R14,24orn) were tested for their activity against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus, their cytotoxic effects on A549, NCI-H441, SAEC epithelial-like cells and normal human lung fibroblasts (NHLF) and their ability to stimulate IL-8 and TGF-β1 release from A549 cells, and to serve as ART1 substrates. HNP and the three analogs had similar effects on IL-8 and TGF-β1 release from A549 cells and were all cytotoxic for SAEC, NCI-H441 and NHLF. HNP-(R14,24orn) when compared to HNP-1 and HNP-1 with a single ornithine substitution for arginine 14 or 24 exhibited reduced cytotoxicity, but it enhanced proliferation of A549 cells and had antibacterial activity. Thus, arginines 14 and 24, which can be ADP-ribosylated by ART1, are critical to the regulation of the cytotoxic and antibacterial effects of HNP-1. The HNP analog, HNP-(R14,24orn) lacks the epithelial cell cytotoxicity of HNP-1 but partially retains its antibacterial activity and thus may have clinical applications in airway disease.